Table 2.
Changes in NPY immunofluorescence with VPA treatment
| Age (d) | Treatment | Change of NPY/NeuN ratio in sections from VPA treated animals (%) | ||||
|---|---|---|---|---|---|---|
| nRt | DG | CX | PVT | PVN | ||
| 32 | Chronic | +16 | — | — | — | — |
| 36 | Chronic | +41 | — | — | — | — |
| 47 | Chronic | +37 | — | — | — | — |
| 24 | Chronic | +23 | +31 | −9 | +7 | −7 |
| 15 | Chronic | +31 | +45 | −5 | +5 | +6 |
| 20 | Acute | −5 | — | — | — | — |
Littermates were used in each trial. Adult (P32–P47): OA, n = 4; VPA, n = 5. Juvenile (P20–P24): chronic: OA, n = 4; VPA, n = 4; acute: OA, n = 4; VPA, n = 4. Young (P14–P15): OA, n = 6; VPA, n = 6. DG, Dentate gyrus; —, not determined.